Randy Teel Sells 9,657 Shares of Arvinas (NASDAQ:ARVN) Stock

13 May 2026, 17:42 by Renee Jackson · The Cerbat Gem

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) CEO Randy Teel sold 9,657 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $95,990.58. Following the transaction, the chief executive officer directly owned 287,218 shares in the company, valued at approximately $2,854,946.92. This trade represents a 3.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Randy Teel also recently made the following trade(s):

On Monday, February 23rd, Randy Teel sold 4,786 shares of Arvinas stock. The stock was sold at an average price of $12.16, for a total transaction of $58,197.76.
On Friday, February 13th, Randy Teel sold 4,403 shares of Arvinas stock. The stock was sold at an average price of $11.89, for a total transaction of $52,351.67.

Arvinas Price Performance

Shares of NASDAQ:ARVN traded up $0.30 during trading on Wednesday, reaching $9.87. 787,117 shares of the company were exchanged, compared to its average volume of 855,453. The firm has a market capitalization of $636.81 million, a PE ratio of -7.71 and a beta of 1.79. The business’s fifty day simple moving average is $11.21 and its 200-day simple moving average is $11.68. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $14.51.

Arvinas (NASDAQ:ARVN – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.05. The business had revenue of $15.60 million for the quarter, compared to analyst estimates of $16.61 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The company’s quarterly revenue was down 91.7% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. On average, sell-side analysts anticipate that Arvinas, Inc. will post -3.25 EPS for the current fiscal year.

Analyst Ratings Changes

ARVN has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Friday, April 10th. Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Wedbush lifted their price objective on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Citigroup lifted their price objective on shares of Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, May 4th. Finally, Truist Financial set a $10.00 price objective on shares of Arvinas in a report on Wednesday, March 18th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $15.14.

View Our Latest Stock Report on Arvinas

Institutional Investors Weigh In On Arvinas

Several institutional investors have recently bought and sold shares of ARVN. Tower Research Capital LLC TRC boosted its stake in Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after acquiring an additional 3,500 shares in the last quarter. State of Wyoming acquired a new stake in Arvinas in the third quarter valued at approximately $68,000. Aster Capital Management DIFC Ltd acquired a new stake in Arvinas in the third quarter valued at approximately $92,000. Finally, Jain Global LLC acquired a new stake in Arvinas in the third quarter valued at approximately $95,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, suggesting meaningful upside from current levels. BTIG raises Arvinas price target
Positive Sentiment: Arvinas and Pfizer struck a licensing deal with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), bringing in $85 million upfront and transition payments plus up to $320 million in additional milestones and royalties. Arvinas and Pfizer deal with Rigel
Positive Sentiment: The company said VEPPANU became the first FDA-approved PROTAC, which validates Arvinas’ drug-degradation platform and supports its pipeline story. Arvinas Q1 2026 results and corporate update
Neutral Sentiment: First-quarter results were mixed: Arvinas reported a smaller-than-expected loss of $0.90 per share, but revenue of $15.6 million missed estimates and fell sharply from a year ago. Arvinas Q1 earnings report
Neutral Sentiment: Investors are also watching pre-earnings commentary and transcript coverage, but these items appear more informational than market-moving on their own. Arvinas earnings call transcript
Negative Sentiment: Despite the product and licensing progress, Arvinas remains unprofitable with weak revenue trends, which may temper enthusiasm for the stock’s longer-term fundamentals. Arvinas earnings expectations

About Arvinas

(Get Free Report)

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.